Craig B. Reeder

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

Alan F. List, Gordon W. Dewald, John M. Bennett et al. · New England Journal of Medicine · 2006 · 1.3K citations

Medicine, Hematology, Pharmacology +17

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Richard Piekarz, Robin Frye, Maria L. Turner et al. · Journal of Clinical Oncology · 2009 · 737 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

Shaji Kumar, Joseph Mıkhael, Francis K. Buadi et al. · Mayo Clinic Proceedings · 2009 · 625 citations · Full text

Medicine, Hematology, Oncology +14

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

Joseph Mıkhael, David Dingli, Vivek Roy et al. · Mayo Clinic Proceedings · 2013 · 495 citations

Medicine, Hematology, Oncology +15

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Thomas E. Witzig, Julie M. Vose, Pier Luigi Zinzani et al. · Annals of Oncology · 2011 · 393 citations · Full text

Medicine, Oncology, Pharmacology +13